PREMPRO (conjugated estrogens and medroxyprogesterone acetate) by Pfizer is estrogen receptor agonists [moa]. First approved in 1995.
Drug data last refreshed 8h ago · AI intelligence enriched 4d ago
PREMPRO is a combination oral hormone replacement therapy (HRT) containing conjugated estrogens and medroxyprogesterone acetate. It works as an estrogen receptor agonist to alleviate menopausal symptoms by replacing declining hormone levels. This classic HRT formulation has been a cornerstone therapy for postmenopausal women for nearly three decades.
As LOE approaches, commercial teams are managing gradual volume erosion with stabilized pricing; smaller, more focused teams expected post-exclusivity.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation
Worked on PREMPRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PREMPRO offers limited career growth opportunities given its LOE trajectory and declining market activity; roles are primarily focused on defending market share, managing payer relationships, and optimizing profitability. This is a consolidation/optimization product rather than a growth driver, suited for professionals seeking stability over expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo